TARTARIC ACID, D-

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C4H6O6
Molecular Weight	150.0868
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O[C@@H]([C@H](O)C(O)=O)C(O)=O

InChI

InChIKey=FEWJPZIEWOKRBE-LWMBPPNESA-N

InChI=1S/C4H6O6/c5-1(3(7)8)2(6)4(9)10/h1-2,5-6H,(H,7,8)(H,9,10)/t1-,2-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17072096
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11149858 | http://www.inchem.org/documents/jecfa/jecmono/v05je93.htm

D-(-)-tartaric acid is isomer of tartaric acid, that industrially produced in the largest amounts. D-(-)-Tartaric acid may be used in the preparation of enantiospecific homochiral cis-4-formyl β-lactams. It may also be used as a starting material in the synthesis of D-erythro-sphingosine and L-lyxo-phytosphingosine. D-(-)-tartaric acid is widely used as an acidizing agent for beverages and other foods, and this use is similar to citric acid. Tartaric acid can be used as an acid dye mordant when it is combined with tannin. It is also used for some development and fixing operations in the photographic industry. D-(-)-Tartaric Acid is used in the preparation of synthetic analgesics. Tartaric acid is metabolically inert in the human body. When taken by mouth, only about 20% of ingested tartrate is eliminated in the urine; the remainder is not absorbed as such since it is destroyed in the intestinal tract by bacterial action. Sodium tartrate in daily doses of up to 10 or even 20 g has been used in medical practice as a laxative.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Unknown 2578

PubMed

Title	Date	PubMed
An efficient and convenient approach to the total synthesis of sphingofungin.	2000 Dec 29	11149858

Patents

Sample Use Guides

In Vivo Use Guide

Sodium tartrate in daily doses of up to 10 or even 20 g has been used in medical practice as a laxative.

Route of Administration: Oral

In Vitro Use Guide

The transepithelial transport ofRhol23 in rat colon was examined using diffusion chamber method. The serosal and mucosal reservoirs were filled with 5 ml. Krebs Henseleit bicarbonate buffer (KHBB) solution, which was continuously circulated and oxygenated by mixed gas (95% 02/5% C02) to maintain tissue viability at pH 7.4 and 37°C throughout the experiments. After 20 min, the KHBB solution was exchanged with 5 ml. KHBB solution containing Rhol23 in the serosal side (donor side) and with 5 ml. KHBB solution without Rhol23 in the mucosal side (acceptor side). In the same experiments, Rhol23 was added to the mucosal side (donor side) but not to the serosal side (acceptor side). To examine the effect of TA (D-(-)-tartaric acid), the mucosal reservoir was filled with KHBB solution containing TA (5 or 10 mM). The pH of KHBB solution containing TA was adjusted to 7.4 using sodium hydroxide. The samples were taken from the acceptor side at intervals of 10 min. Permea¬tion clearance (CLp) was obtained as follows.

Name

Type

Language

TARTARIC ACID, D-

Common Name

English

D-TARTARIC ACID [MI]

Common Name

English

TARTARIC ACID, (-)-

Common Name

English

(-)-TARTARIC ACID

Systematic Name

English

(2S,3S)-2,3-DIHYDROXYBUTANEDIOIC ACID

Systematic Name

English

UNUSUAL TARTARIC ACID

Common Name

English

D-TARTARIC ACID

Systematic Name

English

UNNATURAL TARTARIC ACID

Common Name

English

BUTANEDIOIC ACID, 2,3-DIHYDROXY-, (2S,3S)-

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 331.15